Biosante Pharmacueticals, who are running phase III trials for the latest hopeful in HSDD (hypoactive sexual desire disorder), Libigel ( testosterone gel) have now completed the recruitment part of their trial and now may commence the study which will observe the safety and efficacy of this treatment for menopausal women in relation to cardiovascular and breast cancer safety.
The study will be carried out over a 12 month period beginning after the last person was enrolled and then the analysis will be carried out by Biosante Pharmacueticals.
The company expects to present the Libigel NDA (new drug application) at the end of 2012. We will be updating this page with all of the latest news in FSD (female sexual dysfunction) as soon as it comes in.